{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:07:01Z","timestamp":1775142421297,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>(1) Background: The management of epilepsy during pregnancy requires balancing effective seizure control against potential teratogenic effects of antiseizure medications (ASMs). Data on the safety of lacosamide (LCM), a third-generation ASM, during pregnancy and breastfeeding are limited. (2) Methods: To evaluate the safety and efficacy of LCM during pregnancy and breastfeeding, we report a single-centre case series and provide a comprehensive narrative review of the literature. (3) Results: In total, 22 cases of maternal exposure to LCM throughout pregnancy (1 monotherapy, 21 polytherapy) were identified, resulting in 21 live births (95.5%). Congenital malformations (atrial septal defect) were observed in one offspring exposed to LCM and levetiracetam (4.8%). Twelve newborns were breastfed (57.1%) without neurodevelopmental delay after twelve months. The literature search identified 16 studies, overall reporting data on 627 pregnancies with LCM (236 monotherapy, 391 polytherapy). Among 632 available pregnancy outcomes (3 twin pregnancies and 1 triplet in the polytherapy group) the proportion of live births was 81.3% (514\/632). Major congenital malformations were reported in 2.5% (6\/236) with LCM monotherapy and 11.9% (47\/396) with polytherapy. (4) Conclusions: According to the literature, no major safety concerns, especially in LCM monotherapy, and no specific malformations associated with LCM exposure were identified. Conclusions are limited by the heterogeneity of studies and the small number of monotherapy-exposed cases. Larger, prospective studies with longer follow-up are required.<\/jats:p>","DOI":"10.3390\/pharmacy14020058","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T14:09:54Z","timestamp":1775138994000},"page":"58","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lacosamide Safety During Pregnancy and Breastfeeding: A Single-Centre Experience and Comprehensive Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6972-9504","authenticated-orcid":false,"given":"Kamila","family":"Saramak","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Kaml","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0791-7300","authenticated-orcid":false,"given":"Marina","family":"Peball","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1330-3628","authenticated-orcid":false,"given":"Luisa","family":"Delazer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Walser","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Hussl","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Unterberger","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Astner-Rohracher","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/aogs.13109","article-title":"Women treated for epilepsy during pregnancy: Outcomes from a nationwide population-based cohort study","volume":"96","author":"Artama","year":"2017","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: A prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/epi.12109","article-title":"Antiepileptic drug treatment in pregnancy: Changes in drug disposition and their clinical implications","volume":"54","author":"Tomson","year":"2013","journal-title":"Epilepsia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.18180","article-title":"Epilepsy-pregnancy registries: An update","volume":"66","author":"Perucca","year":"2025","journal-title":"Epilepsia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamaneurol.2024.0258","article-title":"Risk of major congenital malformations and exposure to antiseizure medication monotherapy","volume":"81","author":"Battino","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","article-title":"Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability","volume":"79","author":"Zoega","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(23)00199-0","article-title":"Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: A prospective, observational cohort study","volume":"22","author":"Meador","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e209175","DOI":"10.1212\/WNL.0000000000209175","article-title":"Neurodevelopmental and functional outcomes following in utero exposure to antiseizure medication: A systematic review","volume":"102","author":"Honybun","year":"2024","journal-title":"Neurology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1517\/14656566.2012.667803","article-title":"Pharmacotherapy of the third-generation AEDs: Lacosamide, retigabine and eslicarbazepine acetate","volume":"13","author":"Patsalos","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e213933","DOI":"10.1212\/WNL.0000000000213933","article-title":"Trends in prenatal exposure to antiseizure medications over the past decade: A nationwide study","volume":"105","author":"Shahriari","year":"2025","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e209279","DOI":"10.1212\/WNL.0000000000209279","article-title":"Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication: Practice guideline from the AAN, AES, and SMFM","volume":"102","author":"Pack","year":"2024","journal-title":"Neurology"},{"key":"ref_12","first-page":"e167","article-title":"Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs","volume":"93","author":"Raguideau","year":"2019","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.reprotox.2015.07.068","article-title":"Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy","volume":"57","author":"Ylikotila","year":"2015","journal-title":"Reprod. Toxicol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1684\/epd.2021.1273","article-title":"Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation","volume":"23","author":"Landmark","year":"2021","journal-title":"Epileptic Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/fcp.12971","article-title":"Lacosamide use during breastfeeding: A case report and a literature review","volume":"38","author":"Cercos","year":"2024","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0000000000001840","article-title":"Antiepileptic drugs and intrauterine death: A prospective observational study from EURAP","volume":"85","author":"Tomson","year":"2015","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e207996","DOI":"10.1212\/WNL.0000000000207996","article-title":"Comparative risk of major congenital malformations with antiseizure medication combinations vs valproate monotherapy in pregnancy","volume":"102","author":"Cohen","year":"2024","journal-title":"Neurology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.pjnns.2017.03.003","article-title":"Lacosamide during pregnancy and breastfeeding","volume":"51","author":"Lattanzi","year":"2017","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.reprotox.2020.04.043","article-title":"Lacosamide levels in blood and breastmilk during pregnancy and lactation: A case report","volume":"97","author":"Kohn","year":"2020","journal-title":"Reprod. Toxicol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"108253","DOI":"10.1016\/j.yebeh.2021.108253","article-title":"Lacosamide serum concentrations during pregnancy","volume":"123","author":"Zutshi","year":"2021","journal-title":"Epilepsy Behav."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.seizure.2021.03.011","article-title":"Change in the pharmacokinetics of lacosamide before, during, and after pregnancy","volume":"88","author":"Fukushima","year":"2021","journal-title":"Seizure"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100535","DOI":"10.1016\/j.ebr.2022.100535","article-title":"Anti N-methyl-D-aspartate receptor (NMDAr) encephalitis during pregnancy: A case report","volume":"19","author":"Dono","year":"2022","journal-title":"Epilepsy Behav. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.seizure.2023.02.015","article-title":"Increasing use of newer antiseizure medication during pregnancy: An observational study with special focus on lacosamide","volume":"107","author":"Hoeltzenbein","year":"2023","journal-title":"Seizure Eur. J. Epilepsy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000539510","article-title":"Status Epilepticus and Low-Grade Glioma in the Pregnant State: Case Report and Ethical Considerations","volume":"16","author":"Waack","year":"2024","journal-title":"Case Rep. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5603\/pjnns.97120","article-title":"Outcomes following exposure to lacosamide monotherapy during pregnancy and breastfeeding\u2014A prospective case series","volume":"58","author":"Bosak","year":"2024","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Christensen, J., Zoega, H., Leinonen, M.K., Gilhus, N.E., Gissler, M., Igland, J., Sun, Y., Tomson, T., Alvestad, S., and Bj\u00f8rk, M.-H. (2024). Prenatal exposure to antiseizure medications and fetal growth: A population-based cohort study from the Nordic countries. Lancet Reg. Health\u2013Eur., 38.","DOI":"10.1016\/j.lanepe.2024.100849"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/epi.17924","article-title":"Lacosamide and pregnancy: Data from spontaneous and solicited reports","volume":"65","author":"Perucca","year":"2024","journal-title":"Epilepsia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100741","DOI":"10.1016\/j.ebr.2025.100741","article-title":"The use of newer anti-seizure medicines in women with epilepsy in pregnancy: A case series","volume":"29","author":"Devin","year":"2025","journal-title":"Epilepsy Behav. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Sokol Karadjole, V., AlShaer, D., Snelgrove, J.W., Carmant, L.S., and Moores, G. (2025). New onset refractory status epilepticus diagnosed in the second trimester: A case report. Obstet. Med.","DOI":"10.1177\/1753495X251386551"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e213786","DOI":"10.1212\/WNL.0000000000213786","article-title":"Use of antiseizure medications early in pregnancy and the risk of major malformations in the newborn","volume":"105","author":"Quinn","year":"2025","journal-title":"Neurology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00415-025-13172-3","article-title":"Safety concerns of maternal antiseizure medications exposure on perinatal and offspring outcomes: A disproportionality analysis based on FDA adverse event reporting system","volume":"272","author":"Zeng","year":"2025","journal-title":"J. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ji, Z., Nie, J., Shen, Q., and Fu, Z. (2025). Antiepileptic drugs and foetal disorders: Analysis of 20-year data from the pharmacovigilance center. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1556598"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.seizure.2021.07.002","article-title":"Zonisamide safety in pregnancy: Data from the UK and Ireland epilepsy and pregnancy register","volume":"91","author":"McCluskey","year":"2021","journal-title":"Seizure"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.seizure.2024.03.002","article-title":"Teratogenicity of zonisamide and other little-used antiseizure medications","volume":"117","author":"Vajda","year":"2024","journal-title":"Seizure Eur. J. Epilepsy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ane.12414","article-title":"Lacosamide cardiac safety: Clinical trials in patients with partial-onset seizures","volume":"132","author":"Rudd","year":"2015","journal-title":"Acta Neurol. Scand."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ane.12416","article-title":"Lacosamide cardiac safety: A thorough QT\/QT c trial in healthy volunteers","volume":"132","author":"Kropeit","year":"2015","journal-title":"Acta Neurol. Scand."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","article-title":"Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials","volume":"52","author":"Biton","year":"2015","journal-title":"Epilepsy Behav."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pediatrneurol.2023.09.004","article-title":"Neonatal cardiac arrest following lacosamide treatment: A case report","volume":"149","author":"Huberman","year":"2023","journal-title":"Pediatr. Neurol."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/14\/2\/58\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T14:29:51Z","timestamp":1775140191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/14\/2\/58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["pharmacy14020058"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy14020058","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}